VIVUS Submits NDA (VVUS)

Posted in pre-market 
December 29th, 2009

VIVUS, Inc. (NASDAQ: VVUS) is trading higher this morning after the company announced that it has  submitted its Qnexa new drug application to the FDA for the treatment of obesity. This also includes weight loss and maintenance of weight loss in patients who are obese or overweight with co-morbidities such as hypertension, type 2 diabetes, dyslipidemia or other ailments.  Shares were up more this morning but at 8:30 AM EST we have shares trading up 3.1% at $9.97 on 227,000 shares.  Average volume is 4.1 million shares and the 52-week trading range is $2.72 to $12.88.

JON C. OGG

Comments are closed

-->